Diuril is one of 72 small molecule programs targeting Nephrogenic Diabetes Insipidus. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
687 competitors in Heart Failure
Diuril
Bayer Aspirin
Brethine
Medrol
Amidate
LCZ696
Monoferric
Zemplar
Activase
Savaysa
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Regulatory
Jan 1, 1982
DIURIL
NDA NDA011145
Jan 1, 1982
DIURIL
NDA NDA011870
Sources